Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Drug Insights
4 min read
Sulindac Unveiled: A Detailed Overview of its Revolutionary R&D Breakthroughs
17 September 2023
This article summarized the latest R&D progress of Sulindac, the Mechanism of Action for Sulindac, and the drug target R&D trends for Sulindac.
Valuable Targets
6 min read
CDK7 inhibitor - potential treatment strategy for multiple tumors
17 September 2023
CDK7 is a member of the cell cycle-dependent kinase (CDK) family, and a subunit of the multiprotein basal transcription factor TFIIH.
Drug Insights
4 min read
Unleashing the Power of Spinosad: A Comprehensive Review on R&D Breakthroughs
15 September 2023
This article summarized the latest R&D progress of Spinosad, the Mechanism of Action for Spinosad, and the drug target R&D trends for Spinosad.
Latest Hotspot
3 min read
Ifinatamab Deruxtecan Continues to Demonstrate Durable Responses in Patients with Advanced Small Cell Lung Cancer in Early Trial
15 September 2023
Updated results from a subgroup analysis of a phase 1/2 trial showed that ifinatamab deruxtecan (I-DXd) continues to demonstrate durable responses in patients with heavily pretreated advanced small cell lung cancer.
Drug Insights
4 min read
A Comprehensive Review of Somatostatin's R&D Innovations
15 September 2023
This article summarized the latest R&D progress of Somatostatin, the Mechanism of Action for Somatostatin, and the drug target R&D trends for Somatostatin.
Valuable Targets
6 min read
Advancements in Clinical Research on CDK5 Inhibitors
15 September 2023
CDK5, or cyclin-dependent kinase 5, is a crucial enzyme found in the human body that plays a significant role in various physiological processes.
Drug Insights
4 min read
Pharmaceutical Insights: Silodosin's R&D Progress
15 September 2023
This article summarized the latest R&D progress of Silodosin, the Mechanism of Action for Silodosin, and the drug target R&D trends for Silodosin.
Latest Hotspot
3 min read
Bristol Myers Squibb's trial LPA1 Antagonist reduced lung function decline in Progressive Pulmonary Fibrosis patients in a phase 2 study
15 September 2023
Bristol Myers Squibb's experimental LPA1 Antagonist showed promising results in reducing the rate of lung function decline in the Progressive Pulmonary Fibrosis group in a phase 2 clinical trial.
Drug Insights
4 min read
Exploring Secretin's Revolutionary R&D Successes and its Mechanism of Action on Drug Target
15 September 2023
This article summarized the latest R&D progress of Secretin, the Mechanism of Action for Secretin, and the drug target R&D trends for Secretin.
Valuable Targets
5 min read
CDK4 Inhibitor - A Highly Noticed Breast Cancer Treatment Drug
15 September 2023
CDK4, or cyclin-dependent kinase 4, is a crucial protein involved in cell cycle regulation in the human body.
Drug Insights
4 min read
Decoding Riluzole: A Comprehensive Study of its R&D Trends and Mechanism on Drug Target
15 September 2023
This article summarized the latest R&D progress of Riluzole, the Mechanism of Action for Riluzole, and the drug target R&D trends for Riluzole.
Latest Hotspot
3 min read
Promising results were noted in Phase 1b of the TROPION-Lung04 trial, combining Datopotamab Deruxtecan and Durvalumab for Non-Small Cell Lung Cancer
15 September 2023
Promising clinical responses were observed in TROPION-Lung04's Phase 1b Trial with a combination of Datopotamab Deruxtecan and Durvalumab with Non-Small Cell Lung Cancer.